Second-line therapies of patients with early progression under CDK4/6-inhibitor in first-line – data from the registry platform OPAL.

11. November 2022

Marschner N, Harbeck N, Thill M, Stickeler E, Zaiss M, Nusch A, u. a. 2022.

Oncol Res Treat. 2022;45(suppl 2)(P345):107.

Download